共 50 条
- [21] Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission JOURNAL OF CROHNS & COLITIS, 2019, 13 : S425 - S426
- [23] Treatment Outcome of Tofacitinib Dose Reduction to 5 mg BID vs Remaining on 10 mg BID in Patients With UC Who Were in Stable Remission on 10 mg BID: 6-Month Data From the Double-Blind, Randomized RIVETING Study AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S354 - S354
- [25] Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore JOURNAL OF CROHNS & COLITIS, 2021, 15 : S094 - S095
- [26] Evaluation of the Efficacy of Tofacitinib as Maintenance Therapy in Patients With Ulcerative Colitis Stratified by OCTAVE Sustain Baseline Endoscopic Subscore AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S340 - S340
- [27] Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials JOURNAL OF CROHNS & COLITIS, 2018, 12 : S366 - S367
- [29] Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: An Update of Results From the OCTAVE Clinical Trials AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S332 - S333
- [30] Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S354 - S354